micronavigation ELN path item Treat. Research path item Supportive Care path item Standards/SOP and Recommendations  · 
Workpackage 15: Supportive Care

Standards / SOP 's of Project 15: Supportive Care

Created by: Hellenbrecht (ELIC) , generated 2006/03/14, last changed: 2012/03/26

Power-Point Presentations, provided by Per Ljungman, Karolinska-Institutet / Sweden, February 2007, January 2008, April 2010, October 2011, and January/March 2012

The copyright for any material created by the author is reserved. Any duplication or use of objects such as images, diagrams, or texts in other electronic or printed publications is not permitted without the author's agreement.

Presentations from:

  • 1st European Conference on Infections in Leukemia, 2005, Juan-les-Pins/France
  • 2nd European Conference on Infections in Leukemia, 2007, Juan-les-Pins/France
  • 3rd European Conference on Infections in Leukemia, 2009, Juan-les-Pins/France
  • 4th European Conference on Infections in Leukemia, 2011

Introduction

from ECIL1 to ECIL4

Antiviral Treatment

ECIL4
Susanne Matthes-Martin, Tobias Feuchtinger, Peter Shaw, Dan Engelhard, Per Ljungman
ECIL4
Hans Hirsch, Michael Boeckh, Hermann Einsele, Rodrigo Martino, Kate N Ward, Group leader: Per Ljungman
ECIL4
Dan Engelhard, Mohty Bilal, Rafael de la Camara, Per Ljungman
ECIL4
Working Group: Per Ljungman, Rafael de la Camara, Hermann Einsele, Dan Engelhard, Pierre Reusser, Jan Styczynski, Kate Ward
ECIL4
Working Group: Jan Styczynski, Hermann Einsele, Rafael de la Camara, Catherine Cordonnier, Dan Engelhard, Pierre Reusser, Kate Ward, Per Ljungman
ECIL2
Working Group: Pierre Reusser,Dan Engelhard, Rafael de la Camara, Hermann Einsele, Jan Styczynski,Kate Ward, Per Ljungman
ECIL2
Working Group: Dan Engelhard, Pierre Reusser, Rafael de la Camara, Hermann Einsele, Jan Styczynski,Kate Ward, Per Ljungman

Antifungal Therapy

ECIL4
Working Group: Raoul Herbrecht, Ursula Flückiger, Bertrand Gachot, Patricia Ribaud, Anne Thiebaut, Catherine Cordonnier
ECIL4
Elio Castagnola, Simone Cesaro, Jean-Hugues Dalle, Dan Engelhard, William Hope, Thomas Lehrnbecher, Emmanuel Roilides, Jan Styczynski, Adilia Warris, Co-ordinator: Andreas H. Groll
ECIL3
Working Group: O. Marchetti, C. Cordonnier, T. Calandra
ECIL3
Working Group: Johan Maertens (B, chair), Pascale Frére (B), Cornelia Lass-Flörl (Au), Werner Heinz (D), Oliver Cornely (D, co-chair)
ECIL3
Working Group: F. Lamoth, M. Cruciani, E. Castagnola, O. Lortholary, M. Richardson, O. Marchetti
ECIL3
Working group: Małgorzata Mikulska, Thierry Calandra, Maurizio Sanguinetti, Daniel Poulain and Claudio Viscoli (leader)
ECIL3
Working groups: Galactomannan group (Paul Verweij, Johan Maertens, Thomas Lehrnbecher and Manuel Cuenca-Estrella) and PCR group (Lewis White, Jorgen Loeffler, Lena Klinspor, Rose-Mary Barns and Stéphane Bretagne)
ECIL3
Working Group: A. Skiada, A. Groll, R. Herbrecht, F. Lanternier, O. Lortholary, L. Pagano, S. Zimmerli, G. Petrikkos

Antibacterial Treatment

ECIL4
M Mikulska, M Akova, D Averbuch, G Klyasova, DM Livermore, C Orasch, M Tumbarello, C Cordonnier, WV Kern, C Viscoli, P Munoz, IC Gyssens
ECIL1
A.Cometta, O.Marchetti, T.Calandra

Neutropenia

ECIL1
For the working group Giampaolo Bucaneve

Recommendations

Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia
Bone Marrow Transplant. 2009 May;43(10):757-70. Epub 2008 Dec 1
These guidelines on the management of HSV, VZV and EBV infection in patients with hematological malignancies and after SCT were prepared by the European Conference on Infections in Leukemia following a predefined methodology. A PubMed search was conducted using the appropriate key words to identify studies pertinent to management of HSV, VZV and EBV infections. References of relevant articles and abstracts from recent hematology and SCT scientific meetings were also reviewed. Prospective and retrospective studies identified from the data sources were evaluated, and all data deemed relevant were included in this analysis. The clinical and scientific background was described and discussed, and the quality of evidence and level of recommendation were graded according to the Centers for Disease Control criteria.

Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT
Bone Marrow Transplant. 2008 Aug;42(4):227-40. Epub 2008 Jun 30
These recommendations were prepared by the European Conference on Infections in Leukaemia following a predefined methodology. Literature searches were made to identify studies pertinent to management of CMV, HHV-6, -7 and -8 infections. For CMV, 76 studies were reviewed: 72 published and 4 presented as abstracts. Twenty-nine of these studies were prospective randomized trials. For the other herpesviruses, HHV-6, -7 and -8, no randomized controlled trial has been performed, although data from some studies with other primary endpoints have been used to assess the management of HHV-6 infection. Works presented only as abstracts were used to a very limited extent. The quality of evidence and level of recommendation were graded according to the Center for Disease Control (CDC) criteria.

Quinolone prophylaxis for bacterial infections in afebrile high risk neutropenic patients
EJC Supplements 2007 (Vol. 5, 5-12)
These recommendations have been developed by an expert panel following an evidence-based search of the literature assessing the role of fluoroquinolones in the prevention of bacterial infection in patients with acute leukaemia or bone marrow transplantation and neutropenia. We present results from a questionnaire on the current practice among experts in Europe, show results of the literature search, review recommendations available from other international guidelines and provide the panel’s recommendations.

Empirical antifungal therapy in neutropaenic cancer patients with persistent fever
EJC Supplements 2007 (Vol. 5, 32-42)
Invasive fungal infections are frequent and severe complications in leukaemic patients with prolonged neutropaenia. Empirical antifungal therapy has become the standard of care in patients with persistent fever despite treatment with broad-spectrum antibiotics. For decades amphotericin B deoxycholate has been the sole option for empirical antifungal therapy. Recently, several new antifungal agents became available. The choice of the most appropriate drug should be guided by efficacy and safety criteria. The recommendations from the First European Conference on Infections in Leukaemia (ECIL-1) on empirical antifungal therapy in neutropaenic cancer patients with persistent fever have been developed by an expert panel after assessment of clinical practices in Europe and evidence-based review of the literature. Many antifungal regimens can now be recommended for empirical therapy in neutropaenic cancer patients. However, persistent fever lacks specificity for initiation of therapy. Development of empirical and pre-emptive strategies using new clinical parameters, laboratory markers and imaging techniques for early diagnosis of invasive mycoses are needed.

Primary antifungal prophylaxis in leukaemia patients
EJC Supplements 2007 (Vol. 5, 43-48)
These recommendations have been developed by an expert panel following an evidence-based search of the literature assessing the role of primary antifungal prophylaxis in patients with acute leukaemia or stem cell transplantation. We present results from a questionnaire on the current practice among experts in Europe, show results of the literature search and provide the panel’s recommendations.

Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients
EJC Supplements 2007 (vol.5, 49-59)
An increasing incidence of invasive fungal infections is observed in most immunocompromised patients, and especially leukaemia patients. In order to decrease the mortality due to these infections, the clinicians need to optimise their treatment choices for the most common fungal infections observed in this population: invasive aspergillosis and candidiasis. These recommendations have been developed by an expert panel following an evidence-based search of the literature assessing the role of antifungal therapies in the treatment of patients with acute leukaemia or bone marrow transplantation and invasive candidiasis – including candidaemia – and aspergillosis. We present results from a questionnaire on the current practice among experts in Europe, show results of the literature search and provide the panel’s recommendations.

Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT
Bone Marrow Transplant. 2005 Apr;35(8):737-46.
Over the last 25 years, the numbers of hematopoietic stem cell transplant (SCT) patients have increased rapidly. Infections have been major obstacles for successful transplantation. Thus, infection prevention is very important in transplant recipients. As the results of transplantation have improved, the number of long-term survivors has increased. Vaccination is a potentially important strategy for reducing the risk for vaccine-preventable infections after SCT. The EBMT produced recommendations for vaccination of SCT recipients published in Bone Marrow Transplantation in 1995. This paper updates the previous recommendations based on current knowledge.

 

Print this Document   Sitemap   Contact  
EUTOS
EUTOS for CML is a unique collaboration between the European LeukemiaNet and Novartis Oncology in Europe More ...


 
top